Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.

According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more ...

Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two ...

Those afflicted with advanced muscle-invasive bladder cancer saw a marked decrease in the risk of their cancer progressing or returning when treated with the drug durvalumab, and boasted higher ...